hs-20094
Peptideexperimental
Clinical trial activity
7 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
5
Phase 3
2
Phase 4
0
Earliest trial started Nov 1, 2021 (NCT05116410)
Timeline
Indications
Mechanism of action
GIP agonist
GLP1R agonist
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL6068153 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07156539 | Phase 3 | Sep 30, 2025 | Jiangsu Hansoh Pharmaceutical Co., Ltd. |
| NCT07057674 | Phase 1 | Apr 16, 2025 | Jiangsu Hansoh Pharmaceutical Co., Ltd. |
| NCT06839664 | Phase 3 | Nov 11, 2024 | Jiangsu Hansoh Pharmaceutical Co., Ltd. |
| NCT06901648 | Phase 2 | Feb 6, 2024 | Jiangsu Hansoh Pharmaceutical Co., Ltd. |
| NCT06118021 | Phase 2 | Oct 16, 2023 | Jiangsu Hansoh Pharmaceutical Co., Ltd. |
| NCT06118008 | Phase 2 | May 30, 2023 | Jiangsu Hansoh Pharmaceutical Co., Ltd. |
| NCT05116410 | Phase 1 | Nov 1, 2021 | Jiangsu Hansoh Pharmaceutical Co., Ltd., Peking University |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Jiangsu Hansoh Pharmaceutical Co., Ltd. | For profit | 7 | 7 | 3 | 2021 |
| Peking University | Academic/Hospital | 1 | 0 | 1 | 2021 |
2 organizations
Page 1 / 1